Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “outperform” rating reiterated by equities research analysts at Leerink Swann in a research report issued on Monday. They currently have a $7.00 price target on the stock. Leerink Swann’s price objective would indicate a potential upside of 132.56% from the company’s current price.
Several other research firms have also recently commented on AUPH. FBR & Co restated an “outperform” rating and issued a $9.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, August 15th. Canaccord Genuity set a $10.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. Finally, HC Wainwright started coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They issued a “buy” rating and a $7.00 target price for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $7.75.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 5.32% on Monday, reaching $3.17. The company’s stock had a trading volume of 2,788,442 shares. Aurinia Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $4.49. The stock’s market capitalization is $111.86 million. The stock has a 50-day moving average of $2.23 and a 200 day moving average of $2.74.
A hedge fund recently raised its stake in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp increased its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned 0.29% of Aurinia Pharmaceuticals worth $283,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 20.04% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.